HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $64 Price Target

Benzinga · 10/25 11:10
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $64 price target.